Examining the Knowledge, Attitudes, and Beliefs of Sickle Cell Disease Patients, Parents of Patients With Sickle Cell Disease, and Providers Towards the Integration of CRISPR in Clinical Care
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03167450|
Recruitment Status : Recruiting
First Posted : May 30, 2017
Last Update Posted : January 15, 2019
Sickle cell disease (SCD) is caused by a genetic defect that affects how hemoglobin is made. Due to this, people with SCD have abnormally-shaped red blood cells, which can result in poor oxygen transport in the body and increase risk of blood clots. CRISPR Cas9 is a new tool which allows scientists to snip and edit genes in a way that is faster, cheaper, and more precise than other gene-editing tools. Recently, research has been done using CRISPR Cas9 to correct the sickle cell gene in animal models and human cells. Researchers want to understand the views of those with SCD, parents of people with SCD, and the providers of these patients regarding use of CRISPR Cas9 in clinical trials and treatment.
To study the attitudes, beliefs, and opinions of those with SCD, parents of those with SCD, and providers on the use of CRISPR Cas9 gene-editing. An additional purpose of this study is to assess the utility of an educational tool for improving understanding of CRISPR Cas9.
People ages 18 and older who speak English and either have SCD, are a parent of someone with SCD, or are a physician for people with SCD.
Participants will be screened via phone. Those with SCD will be screened with data from their SCD genotype.
Participation lasts about 2 hours.
Participants will fill out three surveys.
Participants will watch a video about CRISPR Cas9.
Participants will engage in a focus group session. This will be audiotaped and analyzed.
The data from the survey questions and focus groups may be used for future research. However, all personally identifiable information will be removed before data is shared.
Participants data will be identified with a code number instead of their name.
Participants may be invited to join future studies of SCD.
|Condition or disease|
|Sickle Cell Disease|
|Study Type :||Observational|
|Estimated Enrollment :||160 participants|
|Official Title:||Examining the Knowledge, Attitudes, and Beliefs of Sickle Cell Disease Patients, Parents of Patients With Sickle Cell Disease, and Providers Towards the Integration of CRISPR in Clinical Care|
|Estimated Study Start Date :||January 18, 2019|
|Estimated Primary Completion Date :||June 30, 2019|
|Estimated Study Completion Date :||June 30, 2019|
Adults have sickle cell disease
Parents with children/adults who have sickle cell disease
Physicians who have delivered healthcare to individuals living with sickle cell disease for at least a year
- Focus group interviews related to attitudes, beliefs, and opinions of those with SCD, parents of those with SCD, and providers on the use of CRISPR Cas9 gene-editing. [ Time Frame: At the day of inclusion ]
- To assess the utility of an educational tool for improving understanding of CRISPR Cas9. [ Time Frame: At the day of inclusion ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03167450
|Contact: Vence L Bonham, J.D.||(301) email@example.com|
|United States, Maryland|
|National Human Genome Research Institute (NHGRI)||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: Vence Bonham, J.D. 301-594-3973 firstname.lastname@example.org|
|Principal Investigator:||Vence L Bonham, J.D.||National Human Genome Research Institute (NHGRI)|